Abstract Title: currently loading...

information currently loading...

close
Loading ... please wait
timer Loading ... please wait

Free Paper Session 18: New Drug Treatment Session

Date/Time: | Room:

Back to Previous

Title

Theme

14:30:00 P. Stanga United Kingdom Complement C5 inhibition as a potential treatment for autosomal recessive Stargardt disease (STGD1): Design of a clinical trial assessing a novel treatment and primary outcome measure
14:36:00 A. Stahl Germany Ranibizumab for the treatment of retinopathy of prematurity: Twentyfour week, randomized, multicenter, openlabel RAINBOW study
14:42:00 Y. Solberg Switzerland Fluorescence lifetime imaging ophthalmoscopy for the monitoring of lesion progression in Stargardt disease
14:48:00 P. Arendt Switzerland Effect of microglia depletion on the disease course of experimental choroidal neovascularization in mice
14:54:00 B. Kuppermann United States Safety and activity of a single, intravitreal injection of human retinal progenitor cells for treatment of retinitis pigmentosa (RP)
15:00:00 B. Stanzel Germany OCT Histopathologic correlation of Integration of submacular hESCRPE monolayers xenografts in monkeys with a compromised blood retinal barrier
15:06:00 T. Hu Belgium Therapeutic effect of the potent integrin antagonist THR687 in the cynomolgus laserinduced choroidal neovascularization model confirms its potential as novel treatment for sightthreatening retinal pathologies
15:12:00 B. LeRoy Belgium Year 1 time to mobility test completion in a voretigene neparvovec trial in subjects with RPE65 mutation–associated inherited retinal disease
15:18:00 E. Zrenner Germany Experiences with electronic retina implant alpha (RIALPHA) in more than 60 blind patients with inherited retinal dystrophies
15:24:00 U. Kayabasi Turkey Inhibition of mTOR pathway to prevent photoreceptor cell damage
15:30:00 Y. Cheng China A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity
15:36:00 R. Mittal India Role of Endocyclo photocoagulation (ECP) in refractory silicon oil induced glaucoma

Want to find out more about EURETINA activities?

Contact us
© EURETINA All rights reserved